Relmada Therapeutics (RLMD) EPS (Weighted Average and Diluted) (2014 - 2026)
Relmada Therapeutics (RLMD) reported EPS (Weighted Average and Diluted) of -$0.22 for Q1 2026, up 62.07% year-over-year from -$0.14 in Q1 2025, and up 24.14% on a QoQ basis from -$0.29 in Q4 2025.
Relmada Therapeutics (RLMD) has 11 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.22 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 62.07% year-over-year to -$0.22 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.11 (up 55.78% YoY) and the FY2025 annual result came in at -$1.45, up 45.28% from the prior year.
- EPS (Weighted Average and Diluted) improved to -$0.22 in Q1 2026 per RLMD's latest filing, from -$0.29 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.22 in Q1 2026 and bottomed at -$1.35 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.72 (2024), against an average of -$0.76.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) advanced 0.23%; it then surged 62.07% in 2026.
- Tracing RLMD's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.26 in 2022, then surged by 34.13% to -$0.83 in 2023, then advanced by 25.3% to -$0.62 in 2024, then soared by 53.23% to -$0.29 in 2025, then rose by 24.14% to -$0.22 in 2026.
- Per Business Quant, the three latest RLMD EPS (Weighted Average and Diluted) figures stand at -$0.22 (Q1 2026), -$0.29 (Q4 2025), and -$0.3 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.22 |
| Dec 31, 2025 | -0.29 |
| Sep 30, 2025 | -0.30 |
| Jun 30, 2025 | -0.30 |
| Mar 31, 2025 | -0.58 |
| Dec 31, 2024 | -0.62 |
| Sep 30, 2024 | -0.72 |
| Jun 30, 2024 | -0.59 |
| Mar 31, 2024 | -0.72 |
| Dec 31, 2023 | -0.83 |
| Sep 30, 2023 | -0.73 |
| Jun 30, 2023 | -0.84 |
| Mar 31, 2023 | -0.87 |
| Dec 31, 2022 | -1.26 |
| Sep 30, 2022 | -1.31 |
| Jun 30, 2022 | -1.33 |
| Mar 31, 2022 | -1.35 |
| Dec 31, 2021 | -1.80 |
| Sep 30, 2021 | -2.44 |
| Jun 30, 2021 | -1.56 |
| Mar 31, 2021 | -1.35 |
| Dec 31, 2018 | -0.28 |
| Dec 31, 2017 | -0.11 |
| Mar 31, 2017 | -0.16 |
| Dec 31, 2016 | -0.09 |
| Sep 30, 2016 | -0.14 |
| Mar 31, 2016 | -0.15 |
| Dec 31, 2015 | -0.22 |
| Sep 30, 2015 | 0.36 |
| Mar 31, 2015 | -0.23 |
| Dec 31, 2014 | 0.40 |
| Mar 31, 2014 | 0.42 |